ABSTRACT:
Post-COVID-19 Syndrome (PCS), also known as Long COVID, is characterized by a range of persistent symptoms following acute SARS-CoV-2 infection, driven largely by immune dysregulation. This comprehensive review explores key immunological mechanisms underlying PCS, including chronic inflammation, autoimmunity, T-cell exhaustion, gut dysbiosis, and vascular abnormalities. Elevated inflammatory markers such as IL-6 and TNF-α, along with sustained autoantibody production and dysfunctional memory T-cell profiles, suggest ongoing immune activation long after viral clearance. The review highlights additional contributors such as mast cell hyperactivation and persistent viral antigens, which may sustain systemic symptoms. Notably, gut microbiota imbalance and endothelial damage further amplify immune disturbances. While some patients show immune normalization by 24 months, others continue to suffer from debilitating symptoms. Understanding these complex pathways is critical for developing targeted immunotherapies and personalized treatment approaches. This work aims to bridge current findings and support future clinical strategies for managing the multifaceted impact of Long COVID.
Cite this article:
Vandana Kalra (2025), Immune Dysregulation in Post-COVID-19 Syndrome: A Comprehensive Review, Spectrum of Emerging Sciences, 5 (1) 64-69, 10.55878/SES2025-5-1-13DOI: https://doi.org/10.55878/SES2025-5-1-13
Reference:
1. Cañas CA. Post COVID-19 syndrome: Insights
into a novel post-infectious systemic disorder. Front Immunol.
2023;14:10015558.
2. Altmann DM, Boyton RJ. Navigating the Post
COVID-19 immunological era: Understanding Long COVID-19 and immune response.
Life. 2023;13(11):2121.
3. Phetsouphanh C, et al. Immunological
dysfunction persists for 8 months following initial mild to moderate SARS-CoV-2
infection. Nat Immunol. 2022;23:210–216.
4. Haunhorst P, et al. Persistence of dysfunctional
immune response 12 months after SARS-CoV-2 infection and their relationship
with pulmonary sequelae and long COVID. Respir Res. 2022;23:2001.
5. Tsilingiris D, et al. Autoantibodies
against ACE2 in patients with COVID-19. Nat Commun. 2023;14:1234.
6. Bani Hani AH, et al. Unravelling the
complex and unexpected physiopathology of the post COVID-19 condition: A
narrative review. Discov Viruses. 2023;2:17.
7. Su Y, et al. Multiple early factors
anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881–895.e20.
8. Galán M, et al. Chronic inflammation in
post-acute sequelae of COVID-19 modulates gut microbiome. Mol Med. 2023;29:986.
9. Villapol S. Gastrointestinal symptoms
associated with COVID-19: impact on the gut microbiome. Transl Res.
2020;226:57–69.
10. Avdonin PP, Blinova MS, Serkova AA, Komleva LA, Avdonin PV. Immunity
and coagulation in COVID-19. Int J Mol Sci. 2024;25(20):11267, doi:10.3390/ijms252011267.
11. Bergamaschi L, et al. Prolonged T cell
activation and long COVID symptoms independently associate with severe COVID-19
at 3 months. eLife. 2023;12:e85009.
12. Hadjadj J, et al. Impaired type I
interferon activity and inflammatory responses in severe COVID-19 patients.
Science. 2020;369(6504):718–724.
13. Primorac D, Vrdoljak M, Brlek P, Pavelić K, Molnar V, Matišić D,
Erceg Ivkošić D, Parčina M. Adaptive immune responses and immunity to
SARS-CoV-2. Front Immunol. 2022;13:848582. doi:10.3389/fimmu.2022.848582.
14. T-cell exhaustion in ME/CFS and long COVID.
JCI Insight. 2024.
15. Wang EY, et al. Prevalent and persistent
new-onset autoantibodies in mild to severe COVID-19. Nat Commun. 2024.
16. Unger K, et al. Autoantigen profiling
reveals a shared post-COVID signature in fully recovered and long COVID
individuals. JCI Insight. 2023.
17. Vázquez Lara JC, et al. Neurological
autoimmune phenomena following COVID-19 infection and vaccination associated
with anti-ACE2 anti-idiotype antibodies. Front Immunol. 2024.
18. Tunheim GE, et al. Long COVID manifests
with T cell dysregulation, inflammation and... Nat Immunol. 2023.
19. Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL,
Zhan H, et al. Alterations in gut microbiota of patients with COVID-19 during
time of hospitalization. Gastroenterology. 2020;159(3):944–955.e8.
20. Fogarty H, Townsend L, Ni Cheallaigh C,
Bergin C, Martin-Loeches I, Browne P, et al. Persistent endotheliopathy in the
pathogenesis of long COVID syndrome. J Thromb Haemost. 2021;19(10):2546–2553.
21. Phetsouphanh C, Darley DR, Wilson DB, Howe
A, Munier CML, Webb AI, et al. Long-lasting cellular immune dysfunction in
post-acute sequelae of SARS-CoV-2 infection. Nat Immunol. 2023;24(1):85–93.
22. Nalbandian A, Sehgal K, Gupta A, Madhavan
MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome.